HPA021451
Anti-SLC16A3 antibody produced in rabbit
Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
同義詞:
Anti-MCT 3, Anti-MCT 4, Anti-Monocarboxylate transporter 3, Anti-Monocarboxylate transporter 4, Anti-Solute carrier family 16 member 3
登入查看組織和合約定價
全部照片(5)
About This Item
推薦產品
生物源
rabbit
品質等級
共軛
unconjugated
抗體表格
affinity isolated antibody
抗體產品種類
primary antibodies
無性繁殖
polyclonal
產品線
Prestige Antibodies® Powered by Atlas Antibodies
形狀
buffered aqueous glycerol solution
物種活性
rat, human, mouse
技術
immunofluorescence: 0.25-2 μg/mL
immunohistochemistry: 1:200-1:500
免疫原序列
AEEEKLHKPPADSGVDLREVEHFLKAEPEKNGEVVHTPETSV
UniProt登錄號
運輸包裝
wet ice
儲存溫度
−20°C
目標翻譯後修改
unmodified
基因資訊
human ... SLC16A3(9123)
一般說明
The gene SLC16A3 (solute carrier family 16 member 3) is mapped to human chromosome 17q25.3. It belongs to the SLC16A family and is a transmembrane protein. SLC16A3 is expressed in testis, small intestine, lung, brain, heart, kidney, and spleen. SLC16A3 is commonly referred to as MCT4 (monocarboxylate transporter 4).
免疫原
Monocarboxylate transporter 4 recombinant protein epitope signature tag (PrEST)
應用
Anti-SLC16A3 antibody produced in rabbit has been used in: immunohistochemistry, flow cytometry, and immunofluorescence (IF) confocal microscopy to stain human bronchial epithelial cells (HBECs)-short hairpin RNA (shRNA) targeting TP53(shp53 (shp53)-V5-TMPRSS11B cells.
生化／生理作用
MCTs (monocarboxylate transporters) are important for transporting lactate and other monocarboxylates across the cell membrane. MCT4/SLC16A3 (solute carrier family 16 member 3) is involved in the transport of γ-hydroxybutyric acid and L-lactate. SLC16A3 is up-regulated in triple negative breast cancer. It is responsible for maintenance of pH, lactate secretion and non-oxidative metabolism of glucose in cancer cells. In similar manner, androgens induce glycolytic metabolism and lactate export in prostate cancer cells by regulating SLC16A3 expression.
特點和優勢
Prestige Antibodies® are highly characterized and extensively validated antibodies with the added benefit of all available characterization data for each target being accessible via the Human Protein Atlas portal linked just below the product name at the top of this page. The uniqueness and low cross-reactivity of the Prestige Antibodies® to other proteins are due to a thorough selection of antigen regions, affinity purification, and stringent selection. Prestige antigen controls are available for every corresponding Prestige Antibody and can be found in the linkage section.
Every Prestige Antibody is tested in the following ways:
Every Prestige Antibody is tested in the following ways:
- IHC tissue array of 44 normal human tissues and 20 of the most common cancer type tissues.
- Protein array of 364 human recombinant protein fragments.
聯結
Corresponding Antigen APREST75671
外觀
Solution in phosphate-buffered saline, pH 7.2, containing 40% glycerol and 0.02% sodium azide
法律資訊
Prestige Antibodies is a registered trademark of Merck KGaA, Darmstadt, Germany
免責聲明
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
未找到適合的產品？
試用我們的產品選擇工具.
儲存類別代碼
10 - Combustible liquids
水污染物質分類（WGK）
WGK 1
分析證明 (COA)
輸入產品批次/批號來搜索 分析證明 (COA)。在產品’s標籤上找到批次和批號，寫有 ‘Lot’或‘Batch’.。
Franziska Baenke et al.
The Journal of pathology, 237(2), 152-165 (2015-05-13)
Metabolic reprogramming in cancer enhances macromolecule biosynthesis and supports cell survival. Oncogenic drivers affect metabolism by altering distinct metabolic processes and render cancer cells sensitive to perturbations of the metabolic network. This study aimed to identify selective metabolic dependencies in
Chantale Farah et al.
Biomedicines, 10(3) (2022-03-26)
A vast majority of BRAF V600E mutated melanoma patients will develop resistance to combined BRAF/MEK inhibition after initial clinical response. Resistance to targeted therapy is described to be accompanied by specific metabolic changes in melanoma. The aim of this work
J Doyen et al.
Biochemical and biophysical research communications, 451(1), 54-61 (2014-07-25)
(18)Fluor-deoxy-glucose PET-scanning of glycolytic metabolism is being used for staging in many tumors however its impact on prognosis has never been studied in breast cancer. Glycolytic and hypoxic markers: glucose transporter (GLUT1), carbonic anhydrase IX (CAIX), monocarboxylate transporter 1 and
Chantale Farah et al.
International journal of molecular sciences, 24(3) (2023-02-12)
There is currently no consensus to determine which advanced melanoma patients will benefit from immunotherapy, highlighting the critical need to identify early-response biomarkers to immune checkpoint inhibitors. The aim of this work was to evaluate in vivo metabolic spectroscopy using
Kati-Sisko Vellonen et al.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 39(4), 241-247 (2009-12-29)
Monocarboxylate transporters (MCTs) are transmembrane proteins capable of transferring lactate and other endogenous and exogenous monocarboxylates across the cell membrane. The aim of the present study was to assess the expression and transporter role of human MCT1, MCT3 and MCT4
文章
Drug Transport
我們的科學家團隊在所有研究領域都有豐富的經驗，包括生命科學、材料科學、化學合成、色譜、分析等.
聯絡技術服務